Company Overview and News
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
China’s blue-chip CSI300 index was up 0.68 per cent, with its financial sector sub-index higher by 1.32 per cent, the consumer staples sector up 2.42 per cent, the real estate index up 3.25 per cent and healthcare sub-index up 0.58 per cent.
Huaneng Power International, Inc. (NYSE:HNP) has 63 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 251,442,923 shares. Largest shareholders include JP Morgan Chase & Co, Raymond James & Associates, Gabelli Funds Llc, Ajo, Lp, BlackRock Inc., Dimensional Fund Advisors Lp, Guggenheim Capital Llc, Jane Street Group, Llc, Credit Suisse Ag/, and Morgan Stanley.
Hong Kong stocks rose to the highest level in over a decade on Tuesday, aided by a surge in property shares as well as China's H-Share full convertibility reform which is generally viewed as positive to Hong Kong-listed Chinese companies. China stocks also started 2018 trading on a bullish note on better-than-expected December manufacturing activity.
Here are four stocks with buy rank and strong income characteristics for investors to consider today, November 28th:
Here are four stocks with buy rank and strong income characteristics for investors to consider today, November 21st:
Here are four stocks with buy rank and strong income characteristics for investors to consider today, November 8th:
Restructuring of China’s electricity generation industry looks set to come full circle with a reconsolidation of state-owned majors, some of which were established only 15 years ago through the break-up of former behemoth State Power Corporation into five big generation firms.
generation capacity by 60 per cent in three years, with a substantial portion in nations covered by China’s Belt and Road Initiative, according to the chief of its Hong Kong unit.
The company says authorities have not done enough to properly execute the mechanism to link power and coal prices introduced in 2004
China Resources Power (CRP) has posted a 65.3 per cent crash in interim profit, crippled by higher coal costs that could not be offset by higher power prices.
The power generator says the profit decline was primarily due to surge in coal prices and a bigger portion of power sales being subjected to market competition
One of Buffett's best investments was when he doubled down on GEICO at 8x earnings decades ago.
Net profit came in at US$34.89 million, down from US$918 m in the same period last year, far worse than analysts has expected
At Zacks, we understand the importance of discovering undervalued investments for our customers. Many investors constantly seek stocks that not only maintain stability, but produce respectable returns for its shareholders. Luckily, alongside the Zacks Rank, we can use our Style Scores System to search for stocks with an “A” grade in Value.
7h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
8h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
18h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...